Document Page: First | Prev | Next | All | Image | This Release | Search
File: aaaau_02.txtROUTINE UNCLASSIFIED PAGE 02 OF 02 RHDJGAA 1009 003888 16/0049Z IN LOW MALARIA THREAT AREAS. ;B) CHLOROQUINE PHOSPHATE 500 MG (300 MG BASE) (ONE BY MOUTH EACH WEEK STARTED TWO WEEKS PRIOR TO EXPOSURE, CONTINUED WEEKLY DURING EXPOSURE, AND FOR SIX-TO-EIGHT WEEKS POST EXPOSURE). CHLOROQUINE RESISTANT MALARIA IS NOT A PROBLEM IN POTENTIAL OPERATIONAL AREAS. ;3) IF NO MALARIA HAZARD AREA WAS ENTERED, INDIVIDUAL SHOULD RETURN THEIR MALARIA PROPHYLAXIS TO THE ISSUER. THE MEDICAL PERSONNEL IN THE AOR WILL BE THE AUTHORITY FOR DESIGNATING A MALARIA HAZARD AREA AND MAY AUTHORIZE INDIVIDUALS TO STOP (OR START) TAKING MALARIA PROPHYLAXIS. (4) IF MALARIA HAZARD AREA WAS ENTERED, THEN NORMAL TERMINAL PROPHYLAXIS OF EIGHT, WEEKLY DOSES OF 45 MG PRIMAOUINE SHOULD BE ISSUED, IN ADDITION TO CONTINUING DOXYCYCLINE OR CHLOROQUINE, FOLLOWING RETURN TO CONUS. (OVALE AND/OR VIVAX-MALARIA ARE PRESENT IN AOR MALARIA AREAS). 2. MENINGOCOCCAL IMMUNIZATION (QUADRAVALENT, A/C/Y/WI35, NSN 6505 01 2865312) SHOULD BE BROADENED TO INCLUDE ALL DEPLOYING PERSONNEL AS SUPPLIES ALLOW. LACK OF MENINGOCOCCAL IMMUNIZATION WITHIN 5 YEARS SHOULD NOT BE CONSIDERED A DETRIMENT TO DEPLOYMENT OF NONMEDICAL PERSONNEL. 3. POINT OF CONTACT IS MAJ PHILIP A. LA KIEN, NGB/SGP DSN 858-8550. BT #1009 UNCLASSIFIED
Document Page: First | Prev | Next | All | Image | This Release | Search